These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 19619021)

  • 1. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doripenem: a new carbapenem in the treatment of nosocomial infection.
    Mandell L
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S1-3. PubMed ID: 19619016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
    Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
    Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doripenem: position in clinical practice.
    Dedhia HV; McKnight R
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
    Levin AS; Oliveira MS
    Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
    Jones RN; Bell JM; Sader HS; Turnidge JD; Stilwell MG
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):434-9. PubMed ID: 19302927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M; Jones RN; Livermore DM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
    McGowan JE
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S29-37; discussion S64-73. PubMed ID: 16813979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of carbapenems in the treatment of serious infections.
    Baughman RP
    J Intensive Care Med; 2009; 24(4):230-41. PubMed ID: 19617229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation].
    Martínez-Martínez L; Calvo J
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():25-31. PubMed ID: 21130927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.